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Differential methylation of the TRPA1 promoter
in pain sensitivity
J.T. Bell1,2, A.K. Loomis3, L.M. Butcher4, F. Gao5, B. Zhang3, C.L. Hyde3, J. Sun5, H. Wu5, K. Ward1, J. Harris1,
S. Scollen6, M.N. Davies1,7, L.C. Schalkwyk7, J. Mill7,8, The MuTHER Consortium*, F.M.K. Williams1, N. Li5,
P. Deloukas9,10,11, S. Beck4, S.B. McMahon12, J. Wang5,11,13,14, S.L. John3, T.D. Spector1,
Chronic pain is a global public health problem, but the underlying molecular mechanisms are
not fully understood. Here we examine genome-wide DNA methylation, ﬁrst in 50 identical
twins discordant for heat pain sensitivity and then in 50 further unrelated individuals. Whole-
blood DNA methylation was characterized at 5.2 million loci by MeDIP sequencing and
assessed longitudinally to identify differentially methylated regions associated with high or
low pain sensitivity (pain DMRs). Nine meta-analysis pain DMRs show robust evidence for
association (false discovery rate 5%) with the strongest signal in the pain gene TRPA1
(P¼ 1.2 10 13). Several pain DMRs show longitudinal stability consistent with susceptibility
effects, have similar methylation levels in the brain and altered expression in the skin. Our
approach identiﬁes epigenetic changes in both novel and established candidate genes that
provide molecular insights into pain and may generalize to other complex traits.
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A
cute and chronic pain have an impact on 20% of the
population worldwide and represent a signiﬁcant ther-
apeutic and economic challenge1,2. Sensitivity to pain is a
complex phenotype, which reﬂects the contribution of multiple
biological, psychological and environmental risk factors. There is
substantial variation in individual pain sensitivity3, only about
half of which is explained by genetic effects, based on evidence
from animal studies4,5, twin-based heritability estimates6,7 and
genetic association analyses8. Multiple experimental approaches
have been used to study pain mechanisms9,10. Chronic pain is
known to be underpinned by several biological processes that
together serve to amplify pain-related signals. The most well
characterized of these are sensitization of the nociceptive nerve
ﬁbres (that innervate peripheral tissues), sensitization of the
spinal circuits relaying signals associated with tissue damage and
strong cortical modulation reﬂecting expectation, mood and past
history. Recent evidence points to the involvement of epigenetic
mechanisms across these molecular systems, both in the
development and maintenance of pain states11,12.
DNA methylation is an essential epigenetic mechanism, which
in mammals occurs at cytosine residues, predominantly in the
context of CpG dinucleotides. DNA methylation is relevant for
gene expression regulation, genomic imprinting, development
and genomic stability. Emerging epigenome-wide association
studies (EWAS) in humans suggest that epigenetic modiﬁcations
may play a pivotal role in complex traits13. Recent EWAS of DNA
methylation differences in disease-discordant monozygotic (MZ)
twins have identiﬁed potentially differentially methylated regions
(DMRs) in several complex diseases, ranging from diabetes to
schizophrenia14–16. Epigenetic analyses of discordant twins can
provide a powerful study design, but the power of this approach
has not yet been tested in large samples at high resolution. Here
we performed detailed genome-wide analyses of DNA
methylation and identiﬁed modest but consistent and
signiﬁcant DNA methylation changes associated with pain
sensitivity, with implications for epigenetic studies of other
complex traits.
Results
Epigenome-wide association study design. We obtained DNA
methylation sequencing proﬁles in a discovery sample of 25 MZ
twin pairs (50 MZ twins) who were discordant for heat pain
sensitivity (heat pain tolerance42 C between twins) determined
experimentally using quantitative sensory testing (QST)
(Supplementary Fig. S1). QST is commonly used for the assess-
ment of pain sensitivity and the heat pain tolerance response
(measured using the heat pain suprathreshold (HPST)) has been
shown to be a clinically relevant QST measure17. We then
obtained DNA methylation levels in a second independent
sample of 50 unrelated individuals who did not overlap with
the individuals in the discovery sample of MZ twins (Supple-
mentary Fig. S1). Whole-blood DNA methylation patterns
were assayed using methylated DNA immunoprecipitation
followed by deep sequencing (MeDIP-seq), performed
separately in the MZ twin sample and in the sample of
unrelated individuals, resulting in an average of 50 million
paired-end reads per individual in the MZ twin sample and an
average of 25 million single-end reads per individual in the
unrelated sample. We quantiﬁed MeDIP-seq reads to obtain a
score of DNA methylation in overlapping 1 kb bins across the
genome (Supplementary Figs S2 and S3). To identify DMRs
associated with heat pain sensitivity (pain DMRs) we performed
two separate pain-sensitivity EWAS on the two cohorts. To
combine the results from the MZ twin and unrelated individual
cohorts, we pursued a meta-analysis (MA) approach. MA is a
powerful tool for aggregating information from multiple
independent studies18 and is routinely used for pooling
results from genome-wide association studies19, where it has
successfully identiﬁed many disease-associated genetic variants
with small effect sizes, not revealed in the individual
studies20–22. We thereby obtained MA pain DMRs (MAP-
DMRs) that were strongly supported by both cohorts and
further investigated.
Genome-wide patterns of DNA methylation in MZ twins. The
DNA methylation sequencing data allowed us to assess at high
resolution the distribution of DNA methylation patterns across
the genome. We observed greater correlation in DNA methyla-
tion proﬁles within MZ pairs compared with pairs of unrelated
individuals, as expected and consistent with previous studies23
(Fig. 1a–c). At a few genomic regions, the correlation pattern was
reversed (Fig. 1c), potentially highlighting regions of high DNA
methylation turnover. However, at the majority of loci across the
genome DNA methylation patterns were positively correlated
within MZ twins. The intraclass correlation coefﬁcient within MZ
twins across the genome was estimated at 0.064 per 1 kb bin
(Fig. 1b), but the estimates showed variability across different
regions and at different resolutions (Fig. 1a). We assessed
evidence for allele-speciﬁc methylation (ASM) in the discovery
set of 50 MZ twins and observed ASM (Methods) at 37.8% of
tested autosomal heterozygous variants within an individual
(considering only variants that were heterozygous in at least 50%
of the sample). Overall, 106 heterozygous variants had evidence
for ASM in at least 50% of the sample and 499% of these
variants showed concordance for ASM of the same allele (or ASM
skew) within MZ twin pairs (Fig. 1a). As expected, DNA
methylation levels were also strongly correlated with genomic
location and with previously annotated epigenetic variants and
regulatory regions (Fig. 1d and Supplementary Fig. S4), where
CpG islands and promoters had signiﬁcantly reduced levels of
DNA methylation.
Pain-sensitivity epigenome-wide analyses. We tested for asso-
ciation between DNA methylation variation and pain sensitivity
to identify DMRs related to pain (pain DMRs). We ﬁrst per-
formed pain-sensitivity EWAS in the discovery (MZ twin) and
second (unrelated individuals) cohorts separately. In the dis-
covery sample of 50 twins, we compared DNA methylation scores
in 1 kb bins across the genome to pain scores for each individual,
using a linear mixed-effects regression (LMER) model controlling
for family structure (Supplementary Fig. S5 and Supplementary
Table S1). At a permutation-based false discovery rate (FDR) of
5% (nominal LMER P¼ 8.4 10 9), there was one signiﬁcant
pain DMR in an intergenic region on chromosome 3 (LMER
P¼ 8.4 10 9). Among the remaining top-ranked pain DMRs
was MVP (ranked fourth; LMER P¼ 7.9 10 8), which is
involved in the interferon-g signalling pathway24, previously
implicated in neuropathic pain25. We also estimated pain DMRs
within speciﬁc genomic annotation categories (CpG islands,
CpG-island shores, and promoters) and found that the top-
ranked regions included the pain gene TRPA1 (ranked fourth,
CpG-island shores, LMER P¼ 3.9 10 5) and other potential
pain candidates (BAIAP2 (ranked ﬁrst, CpG islands, LMER
P¼ 4.9 10 5) and GRIN1 (ranked ninth, CpG islands, LMER
P¼ 2.9 10 4); Supplementary Methods). Among the 100 top-
ranked regions in the CpG-island shore analysis were two
additional known pain genes: the heat pain sensitivity gene
TRPV1 (ranked 31st, CpG-island shores, LMER P¼ 2.3 10 4)
and TRPV3 (ranked 87th, CpG-island shores, LMER
P¼ 6.6 10 4), both within the same family of transient
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receptor potential channels as TRPA1. We then performed a
pain-sensitivity EWAS in the second sample of 50 unrelated
individuals and identiﬁed 22 pain DMRs at a permutation-based
FDR of 5% (LMER P¼ 2.5 10 7; Supplementary Fig. S6 and
Supplementary Table S2). The most associated pain DMR in the
unrelated samples was in ANK3 (LMER P¼ 1.9 10 8), which
is required for normal clustering of voltage-gated sodium
channels and normal action potential ﬁring in neurons26, and is
a susceptibility locus for bipolar disorder27. Pain DMRs in the
second cohort also included DCLK1 (ranked ninth, LMER
P¼ 1.2 10 7), which is a candidate gene for inﬂammatory
nociception in mice28. To explore potential structure and
confounders in the second cohort of unrelated individuals, we
tested whether including multiple principal components altered
the EWAS ﬁndings. We found that including the ﬁrst up to third
principal components as covariates did not change the top
22 association signals (Supplementary Fig. S6 and Supplementary
Table S3).
We explored the sensitivity of EWAS results to potential
confounders. We tested the inﬂuence of methylation normal-
ization and the inclusion of covariates such as age, but did
not ﬁnd signiﬁcant alterations in the top-ranked results
(Supplementary Methods). To assess the sensitivity of pain
DMRs to methylation quantiﬁcation of MeDIP-seq data, we also
performed analyses controlling for CpG density29 and MeDIP-
seq fragment size in the discovery sample (Supplementary
Figs S7 and S8), and found that the majority of top-ranked
pain DMRs remained nominally signiﬁcant, although their
relative rank could change. For example, the TRPA1 pain DMR
(originally ranked 50th, LMER P¼ 2.6 10 6) was nominally
signiﬁcant when controlling for MeDIP-seq fragment size
(ranked 49th, LMER P¼ 2.6 10 6) and CpG density (ranked
36,921st (in top 0.07%), LMER P¼ 7.8 10 3).
To validate DNA methylation signals based on high-resolution
MeDIP-seq, we obtained DNA methylation proﬁles measured on
the Illumina Inﬁnium 450k BeadChip assay30 in 44 individuals
from the discovery sample. We compared genome-wide DNA
methylation obtained from MeDIP-seq and 450k platforms in
1-kb regions genome wide and observed positive correlations
(mean linear correlation¼ 0.62) within individuals at 422,158
one-kilobase regions genome wide (Fig. 1e). The comparisons
were performed using mean level of DNA methylation in 1-kb
regions where data were available on both platforms (which
included only 10% of regions assayed by MeDIP-seq and over
99.9% of CpG sites on the Illumina 450k array). We also
performed EWAS for pain sensitivity using the Illumina 450k
DNA methylation data, but the results did not surpass
permutation-based FDR 5% (Supplementary Fig. S9). However,
most MeDIP-seq pain DMRs were not represented on the 450k
array and only two of the top ten discovery pain DMRs
overlapped a 450k CpG site.
Pain sensitivity MA. We combined the EWAS results from the
two cohorts using a ﬁxed-effect epigenome-wide association MA
in the combined sample of 100 individuals (Fig. 2a). There were
nine MAP-DMRs with compelling evidence for association at a
permutation-based MA threshold of FDR¼ 5% (MA P¼ 2.0
 10 11), excluding results with evidence for heterogeneity. The
nine MAP-DMRs mapped to eight unique regions in the TRPA1
promoter (MA P¼ 1.2 10 13), in an intergenic region on
chromosome 18 (MA P¼ 4.1 10 13), 17 kb from the OR8B8
transcription start site (TSS) (MA P¼ 3.4 10 12), 47–48 kb
from the ST6GALNAC3 TSS (MA P¼ 4.4 10 12), in an intron
of MTMR12 (MA P¼ 5.1 10 12), in an intergenic region on
chromosome 4 (MA P¼ 5.6 10 12), 33 kb from the MICAL2
TSS (MA P¼ 7.2 10 12) and 18 kb from the NFU1 TSS (MA
P¼ 1.2 10 11; Table 1). In the majority of regions, DNA
methylation levels were greater in individuals with low pain
scores (hypermethylated MAP-DMRs). We assessed repeat
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Figure 1 | DNA methylation in MZ twins. CpG-density-weighted DNA methylation levels in 25 MZ discovery twin pairs showing. (a) DNA methylation
(blue inner circle), within-pair MZ intraclass correlation (ICC) (red middle circle) and ASM levels (green outer circle). Methylation levels using
running medians in 1-Mb windows are shown from low (AMS¼0, light blue) to high (AMS¼ 1,000, blue), and MZ ICCs are plotted from 0.25 (inner red
circle radius) to 0.3 (outer red circle radius). ASM green circle represents the proportion of individuals that show evidence for ASM from 0.8 (light green)
to 1 (green) at the 106 SNPs. (b) Genome-wide distribution of MZ ICCs and (c) correlations within MZ twins and unrelated pairs in the discovery
MZ twin cohort (box shows the 25 and 75% quantiles and whiskers extend to 1.5 times the inner quartile range (IQR)). (d) DNA methylation levels
across genomic annotations. (e) Within-individual MeDIP-seq and Illumina-450k DNA methylation comparison, showing the density of points in blue.
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content at MAP-DMRs (Table 1) and identiﬁed three MAP-
DMRs (inMTMR12, NFU1 and on chromosome 4) in high repeat
content regions (450% repeats). In addition, the second and
third top-ranked MAP-DMRs (on chromosome 18 and in
OR8B8) had low repeat content (o30%), but the DMR bound-
aries and surrounding genomic regions had high repeat
content, which may inﬂuence DNA methylation quantiﬁcations.
We also repeated the MA using the second sample EWAS
corrected for methylation principal components and observed
that the nine MAP-DMRs remained top ranked (Supplementary
Table S4).
The strongest association signal was in the promoter of the ion
channel gene TRPA1 (Fig. 2b,c). TRPA1 is a ligand-gated ion
channel selectively expressed in peripheral nociceptors31,32 but
also present in some non-neuronal cells, including
keratinocytes33. The TRPA1 promoter pain DMR in our data
was hypermethylated in individuals with lower pain thresholds,
and promoter DNA methylation can downregulate gene
expression34. To assess whether promoter DNA methylation
differences in TRPA1 reﬂected functional consequences in pain,
we obtained gene expression data from skin biopsies in 341
unselected normal female twins35. We observed a modest
nominally signiﬁcant (LMER P¼ 0.03) increase in TRPA1 gene
expression levels in individuals with higher pain thresholds
(Fig. 2d), consistent with the hypermethylated pain DMR result.
Although TRPA1 has not been reported as a heat sensor in
mammals, it can be regulated by and interact with the
thermosensor TRPV1 (ref. 36), which is also expressed in
keratinocytes. Therefore, we considered evidence for differential
methylation and expression at the three reported thermosensors
TRPV1, TRPV2 and TRPV3. We observed MAP-DMR effects in a
TRPV1 intron (chr17:3,425,000–3,426,000 bp, MA b¼ 0.16,
P¼ 6.7 10 4), 7 kb from the TRPV2 TSS (chr17:16,251,500–
16,252,500 bp, MA b¼ 0.12, P¼ 3.2 10 3) and in a TRPV3
intron (chr17:3,398,500–3,399,500bp, MA b¼ 0.13, P¼ 8.2 10 3),
as well as nominally increased expression of TRPV2 in the skin
(P¼ 0.01), which was consistent with TRPA1 expression results.
We also examined evidence for differential methylation at 73
known pain candidates from animal models, molecular and
genetic studies (Supplementary Fig. S10), and observed
differential methylation in several pain candidate genes,
including KIAA0564 (MA P¼ 2.9 10 5), GRIA1 (MA
P¼ 2.9 10 5), CACNA2D3 (MA P¼ 8.4 10 5), PRDM16
(MA P¼ 9.4 10 5) and P2RX3 (MA P¼ 9.9 10 5).
Whole blood is a heterogeneous collection of cells and DNA
methylation levels within particular genomic regions may in part
reﬂect the cellular composition of the sample. To assess the extent
of these associations in our data, we tested for association
between white blood cell (WBC) subtype counts for lymphocytes,
neutrophils, basophils and eosinophils, and DNA methylation
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Figure 2 | Meta-analysis pain EWAS results. (a) EWAS results and FDR 5% threshold (red line). (b,c) Differential methylation in TRPA1 in pain sensitivity,
showing (b) MeDIP-seq hypermethylation (blue) effects in the discovery set (co-twins linked by lines). (c) Pain DMR validates in the bisulphite sequencing
data from CpG site at chr8:73151235 bp (pain-DMR rank correlation¼0.22 and association taking into account twin structure, P¼0.03). (d) Gene
expression increases (LMER P¼0.03) with higher pain thresholds in 341 twins.
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levels at the nine FDR 5% MAP-DMRs in the discovery sample.
We did not observe signiﬁcant associations between DNA
methylation at the nine MAP-DMRs with proportion of
neutrophils, eosinophils or monocytes, but one of the MAP-
DMRs, the intergenic MAP-DMR on chromosome 4 ranked 6th
in Table 1, was associated with lymphocyte counts (LMER
P¼ 0.003). We conclude that variability in WBC subtypes does
not have a major effect on the top-ranked pain sensitivity DMRs
in our study.
DMR validation by deep bisulphite pyrosequencing and Illu-
mina 450k arrays. To validate DNA methylation levels obtained
by MeDIP-seq at MAP-DMRs, we ﬁrst compared MeDIP-seq
with Illumina 450k DNA methylation estimates. However, only
two MAP-DMRs (in TRPA1 and MICAL2) had a single CpG site
represented on the Illumina 450k platform within the 1-kb
DMR. The MICAL2 MAP-DMR did show a positive correlation
in DNA methylation levels across the two platforms (rank
correlation¼ 0.25). To validate DNA methylation levels at the
TRPA1 MAP-DMR, we performed bisulphite pyrosequencing of
700 bp in the 1-kb MAP-DMR region. We validated DNA
methylation levels at two CpG sites in a 200-bp region within the
CpG-island shore (Fig. 2c and Supplementary Fig. S11). The CpG
sites that validated the MeDIP-seq signal were not represented on
the Illumina 450k array, but six other CpG sites on Illumina 450k
that were within 500 bp of the TRPA1 DMR boundary outside the
DMR validated MeDIP-seq levels. We also considered validation
by examining the direction of pain DMR effects in the EWAS
results from the Illumina 450k platform at CpG sites allocated
to the same gene as the MAP-DMRs. We found that four of
the six genes (based on FDR 5% MAP-DMRs, that is, TRPA1,
ST6GALNAC3, MTMR12 and MICAL2) had consistent direction
of pain-methylation associations in both MeDIP-seq and Illumina
450k platforms, and 52% of the 100 top-ranked gene-based MAP-
DMRs validated using this approach.
Exploring molecular mechanisms underlying DMRs. The pain
DMRs identiﬁed in our study may contribute to pain sensitivity or
arise as a consequence of pain. To tackle this question, we assessed
whether DNA methylation levels at MAP-DMRs showed evidence
of association with genetic variants in cis. We tested for methy-
lation quantitative trait loci (meQTLs) in 47 unrelated individuals
from the second cohort using common genetic variants (minor
allele frequency Z0.05) within 50 kb of the 9 MAP-DMRs. Six
MAP-DMRs had evidence for cis meQTL effects, including
OR8B8 (meQTL P¼ 5.8 10 6), both ST6GALNAC3 DMRs
(meQTL P¼ 3.0 10 5) and modest effects at MAP-DMRs on
chromosome 4 (meQTL P¼ 0.01), in TRPA1 (meQTL P¼ 0.03)
and on chromosome 18 (meQTL P¼ 0.03; Supplementary Table
S5). In comparison, 56% of the top 100 MAP-DMRs were asso-
ciated with genetic variants in cis at nominal signiﬁcance.
Differential methylation in pain sensitivity may also mediate or
reﬂect environmental or unknown non-genetic risk factors in
pain. Our data allowed us to explore such effects by comparing
MZ twins, who are matched for most genetic variation, age,
cohort and many early-life environmental effects. We compared
within-pair differences in DNA methylation and heat pain
tolerance in the discovery set, and observed an enrichment of
negative correlations between methylation and heat pain
tolerance twin differences, consistent with predominantly hyper-
methylated effects (Supplementary Fig. S12), including results at
the FDR 5% MAP-DMRs (Table 1). Several of the 100 top-ranked
MAP-DMRs (MVP, DTNA, GLYATL1, FHIT, FBXO15 and
TMEM132D), as well as known pain candidates such as TRPM3,
GRIA1 and GRIA4 had strong evidence for association between
within-pair differences in methylation and pain levels (P¼ 1.0
 10 5). We found no evidence of correlation between within-
pair ASM skew and heat pain tolerance difference.
Longitudinal DNA methylation proﬁles to assess DMR stabi-
lity. To examine further the stability and potential contribution of
Table 1 | Meta-analysis DMRs for pain sensitivity at FDR 5%.
Discovery (n¼25 MZ pairs)* Follow-up (n¼ 50 individuals)* Meta-analysis*
Chr DMR Nearest gene
(kb)w
%
Repeatz
b s.e.
(b)
P-value MZ
diff
(r)y
b s.e.
(b)
P-value R2 b s.e.
(b)
P-value
8 73,151,000–
73,152,000
TRPA1 (0.1) 0.00 0.23 0.04 2.6 106 0.68 0.40 0.07 1.3 10 6 0.39 0.28 0.04 1.2 10 13
18 5,039,500–
5,040,000
NA 0.10 0.20 0.04 2.6 106 0.77 0.27 0.09 3.2 10 3 0.17 0.21 0.03 4.1 10 13
11 123,833,500–
123,834,500
OR8B8 (17.3) 0.30 0.26 0.04 2.3 10 7 0.85 0.12 0.09 2.0 10 1 0.03 0.24 0.03 3.4 10 12
1 76,264,000–
76,265,000
ST6GALNAC3
(48)
0.23 0.19 0.03 3.5 106 0.71 0.28 0.08 1.6 10 3 0.19 0.20 0.03 4.4 10 12
5 32,273,500–
32,274,500
MTMR12 (0) 0.87 0.24 0.04 2.7 10 5 0.77 0.34 0.08 8.4 10 5 0.28 0.26 0.04 5.1 10 12
4 165,977,000–
165,978,000
NA 0.78 0.24 0.04 2.1 10 7 0.79 0.12 0.09 2.1 10 1 0.03 0.22 0.03 5.6 10 12
11 12,054,000–
12,055,000
MICAL2
(33.7)
0.43 0.27 0.04 5.5 108 0.59 0.22 0.09 1.4 10 2 0.12 0.26 0.04 7.2 10 12
1 76,264,500–
76,265,500
ST6GALNAC3
(47)
0.31 0.18 0.03 5.3 106 0.68 0.28 0.09 2.0 10 3 0.18 0.20 0.03 1.1 10 11
2 69,530,500–
69,531,500
NFU1 (12.2) 0.89 0.24 0.04 8.7 10 7 0.68 0.32 0.08 2.3 104 0.25 0.26 0.04 1.1 10 11
DMR, differentially methylated region; FDR, false discovery rate; MZ, monozygote; NA, not applicable; LMER, linear mixed-effects regression; TSS, transcription start site; HPST, heat pain suprathreshold.
*Coefﬁcients, s.e. and P-values are based on LMER (discovery), linear models (follow-up) and ﬁxed-effect meta-analysis of the two samples.
wNearest gene within 100 kb of the DMR (distance (kb) to nearest TSS from DMR boundary).
zRepeat content estimated as the proportion of ‘N’ bases in each 1 kb DMR bin.
yPearson’s correlation coefﬁcient comparing MZ differences in methylation and HPST.
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epigenetic effects towards pain sensitivity, we obtained long-
itudinal MeDIP-seq and heat pain tolerance data for 33 indivi-
duals from the discovery set, sampled 2–3 years apart. We
compared longitudinal differences in DNA methylation with
longitudinal differences in HPST and found that the 100 top-
ranked MAP-DMRs clustered in three groups (Fig. 3a). Although
B25% of regions had highly variable methylation over time, the
majority of MAP-DMRs remained relatively stable and 15%
showed a modest loss of methylation over time. Longitudinal
DNA methylation patterns at the nine MAP-DMRs showed
relatively stable methylation over time (Supplementary Fig. S13).
At speciﬁc regions within the 100 top-ranked MAP-DMRs heat
pain tolerance, changes were lower in individuals in whom DNA
methylation remained stable over time and higher in individuals
whose DNA methylation levels signiﬁcantly changed with time,
consistent with a model of epigenetic contribution to pain
sensitivity. Altogether, there were at least 18 regions at which the
longitudinal data were consistent with epigenetic susceptibility to
pain, including MAP-DMRs in MICAL2, MVP and KCNE4
(Fig. 3b and Supplementary Table S6).
DNA methylation levels across tissues. Another factor in the
current study was the relevance of DNA methylation changes
observed in whole blood to heat pain tolerance. We therefore
compared DNA methylation proﬁles of the most signiﬁcant loci
identiﬁed here (the MAP-DMRs) in blood and multiple brain
regions from two female donors37, who were not part of the
cohorts used in our EWAS results. We observed a signiﬁcant
positive correlation between mean level of methylation in blood
and brain across the 100 top-ranked MAP-DMRs (linear
correlation coefﬁcient¼ 0.33, P¼ 8.5 10 4). Moreover, ﬁve of
the nine signiﬁcant MAP-DMRs had very similar methylation
levels in the blood and brain (Supplementary Methods). There
was signiﬁcant variability in methylation levels across the
multiple brain tissues at the top 100 MAP-DMRs, and the
observed differences between blood and brain were as extreme as
the methylation differences seen between cerebellum and other
brain regions. Skin gene expression levels at MAP-DMR genes
also showed negative correlations with DNA methylation,
suggestive of potential functional effects. Together, these
observations suggest that whole-blood DNA methylation levels
at the MAP-DMRs are generally relevant to other biological
tissues in the context of our study.
Discussion
The aim of this study was to identify genomic regions that are
differentially methylated in pain sensitivity. We hypothesized that
DNA methylation changes may lead to or arise as a consequence
of heat pain tolerance and thereby identify known and novel
candidate genes involved in pain sensitivity. We characterized
genome-wide DNA methylation proﬁles using MeDIP-seq in 100
individuals and compared these proﬁles with clinically validated
measures of pain sensitivity. We used a two-stage EWAS design
and combined our ﬁndings into an MA, which identiﬁed nine
regions (MAP-DMRs) at a genome-wide signiﬁcant FDR of 5%.
DNA methylation levels at MAP-DMRs were validated using
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Figure 3 | Longitudinal stability of pain DMRs. (a) DNA methylation differences (MEDIPS AMS) over 2–3 years in 33 discovery set individuals (columns),
ordered by longitudinal differences in HPST scores (bar plot). Heatmap rows correspond to the 100 top-ranked MAP-DMRs, where the top 25% are
highly variable and show loss (blue) and gain (red) of methylation over time. (b) Eighteen MAP-DMRs with greater HPST differences in individuals
(nZ6) with variable methylation (change 30–100%) over time (green), compared with HPST differences in individuals with stable methylation
(change 0–30%) over time (grey). Box shows the 25 and 75% quantiles and whiskers extend to 1.5 times the IQR.
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bisulphite-conversion methods. These regions also showed DNA
methylation stability over time, consistent with susceptibility
effects on measured pain sensitivity. Similar levels of DNA
methylation were observed in blood and brain tissues at multiple
pain DMRs, and negative correlations between gene expression
and pain-DMR DNA methylation were observed at pain-DMR
genes in the skin.
Overall, the strongest association MA signal was in the
promoter of the ion channel gene TRPA1. TRPA1 is a ligand-
gated ion channel, which is directly gated by a range of irritants
and noxious cold, and may also gate pain-related responses to a
range of G-protein-coupled receptors. In some species, TRPA1
acts as a heat sensor, for example, TRPA1 is required for thermal
nociception in Drosophila38–40, where a particular TRPA1
isoform acts to reduce thermosensitivity38. Although TRPA1
has not been reported as a heat sensor in mammals, it can
be regulated by and interact with the thermosensor TRPV1
(ref. 36). Both TRPA1 and TRPV1 are expressed in peripheral
nociceptors31,32 but are also present in some non-neuronal cells,
including keratinocytes33. Therefore, we considered evidence for
differential methylation and expression at TRPA1, and the three
thermosensors TRPV1, TRPV2 and TRPV3 in the skin. We
observed nominally signiﬁcant increased expression levels of
TRPA1 in the skin at higher pain thresholds, which is consistent
with a downregulatory effect of DNA methylation in the TRPA1
promoter pain DMR on TRPA1 gene expression. We were not
able to measure TRPA1 expression in nociceptors. TRPV1,
TRPV2 and TRPV3 had modest evidence for pain-DMR effects
in whole-blood DNA methylation, suggesting an involvement of
these thermosensors in differential pain sensitivity in our sample.
In summary, our ﬁndings suggest the presence of a regulatory
DNA methylation region in a CpG-island shore of the TRPA1
promoter, which may have an impact on TRPA1 gene expression
and thermal sensitivity.
Our MA results included additional regions, which are
compelling candidate genes for pain sensitivity. The fourth most
associated MAP-DMR was 47 kb from the TSS of the ST6GAL-
NAC3 gene. ST6GALNAC3 catalyses the transfer of sialic acids to
carbohydrate groups on glycoproteins and glycolipids41. It was
recently identiﬁed as a candidate gene for subcutaneous fat
thickness in pigs42, suggesting that it may be a novel candidate for
heat pain sensitivity in skin. The seventh most associated MAP-
DMR was 33 kb from the TSS of MICAL2, which has a role in
molecular processes highly relevant to pain sensitivity. MICAL
proteins can control actin cytoskeleton dynamics and several
aspects of neural development43, for example, in Drosophila,
MICAL is required for axon guidance44 and is an essential
regulator of synaptic structure along muscle ﬁbres44, and
contributes to dendritic pruning45. We also examined the 100
top-ranked MAP-DMRs (FDR¼ 14%, P¼ 3.0 10 8), which
mapped to 53 genes, including TRPA1 and SCN10A pain genes,
and other genes linked to metal ion transport and binding
(MICAL2, KCNE4, CDH11, COL18A1, DTNA, FHIT, KEL,
PCDH7, PLG and SLC8A1), which are key processes in pain
pathways, as well as cytoskeleton and cell adhesion, which may
inﬂuence or mediate pain sensitivity. Gene ontology analyses46
highlighted signiﬁcant term enrichment for several processes,
including vasoconstriction.
The majority of epigenetic studies of human traits published to
date have used whole blood, as it is often the only sample type
that is available in many human cohorts. However, the suitability
of blood as an appropriate tissue for epigenome-wide association
studies of complex traits has been debated. Blood is a
heterogeneous collection of cells, and DNA methylation levels
may in part reﬂect cellular composition47. We assessed evidence
for this using the top nine FDR 5% MAP-DMRs, but did not
observe signiﬁcant associations between DNA methylation levels
and the proportion of lymphocytes, neutrophils, basophils and
eosinophils. Therefore, variability in WBC subtypes did not
appear to have a major effect on the top-ranked pain sensitivity
DMRs in our study. Aside from blood cell-subtype heterogeneity,
another issue is whether blood is the appropriate surrogate for the
tissue manifesting the phenotype of interest48. In terms of pain
sensitivity, we would ideally explore DNA methylation levels in
nociceptors, peripheral nerve, dorsal root ganglion and the central
nervous system, but these tissues were not available for the
subjects in our study and, to our knowledge, such data have not
been explored in humans in the context of pain. Therefore, we
tested whether our peak DMRs had consistent levels of DNA
methylation or gene expression in whole blood, multiple brain
tissues and the skin. We concluded that many of the top-ranked
DMRs showed consistent methylation or expression changes
across blood and tissues relevant to pain, but further epigenetic
studies in pain need to address this question genome wide across
tissues.
We explored molecular mechanisms that may underlie DMRs
for pain sensitivity. DNA meQTL analysis at the nine MAP-
DMRs indicated the presence of strong genetic effects at MAP-
DMRs in OR8B8 and ST6GALNAC3, and modest genetic effects
at TRPA1 and two intergenic MAP-DMRs on chromosomes 4
and 18. Consistent with this, a second set of MAP-DMRs showed
strong association in the MZ discordance analyses, which aim to
identify MAP-DMRs that are not genetically determined.
Together, this pair of analyses allow us to differentiate between
regions at which genetic effects on pain sensitivity may be
mediated through DNA methylation, and regions at which DMRs
for pain sensitivity may have an environmental cause or may arise
secondary to phenotype variation.
Longitudinal analyses at the 100 top-ranked MAP-DMRs were
consistent with susceptibility DMR effects on pain sensitivity at
multiple genomic regions, but it is difﬁcult to establish
susceptibility in the absence of a phenotype-onset time point.
However, these results clearly highlighted the presence of both
longitudinally stable and variable regions (Fig. 3a), of which the
top nine MAP-DMRs were predominantly stable. As expected,
the majority of MAP-DMRs with meQTLs showed evidence for
longitudinal stability (Fig. 3), but a proportion of the top-ranked
MAP-DMRs in the MZ discordance results was also long-
itudinally stable. We also attempted to identify MAP-DMRs with
potential susceptibility effects, that is, where heat pain tolerance
changes were lower in individuals in whom DNA methylation
remained stable over time and higher in individuals in whom
DNA methylation levels signiﬁcantly changed with time,
consistent with a model of epigenetic contribution to pain
sensitivity.
In summary, we observed strong evidence for association
between DNA methylation levels and pain-sensitivity scores in a
data set of 100 individuals. DNA methylation levels at a subset of
MAP-DMRs showed longitudinal correlation with heat pain
tolerance stability, genetic associations in cis, similar patterns
across blood and brain tissues and correlations with skin gene
expression. Taken together, the results at these DMRs are con-
sistent with an epigenetic inﬂuence on sensitivity to pain in normal
human volunteers. Our ﬁndings conﬁrm that susceptibility genes
identiﬁed from epidemiological studies of complex traits show
epigenetic modiﬁcations with probable functional alterations. Most
of these regions identiﬁed were not represented on the Illumina
450k array, suggesting that a higher-density screening approach is
essential to capture relevant methylation loci. These data have
implications for other complex traits and suggest that epigenomic
approaches may provide valuable insights into mechanisms linking
genetic variation to complex phenotypes.
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Methods
Subjects. All participants in the study provided written informed consent in
accordance with the St Thomas’ Hospital Local Ethics Committee. Altogether,
100 volunteer, female MZ and dizygotic twins from the TwinsUK cohort49
were included in the study, including a discovery set of 50 MZ twins (25 MZ pairs)
and a second independent set of 50 unrelated individuals. QST for heat pain
tolerance was performed according to standard protocols (Supplementary Methods
and included measures of the HPST. The discovery 25 MZ twin pairs (median age
62 years) were selected as the most discordant MZ twin pairs for HPST scores in
the TwinsUK cohort at the time of the study (Supplementary Fig. S1). Discordance
was deﬁned as a difference of at least 2 C in HPST scores, and one twin in each
pair fell in the upper tail of the HPST distribution (low pain sensitivity). The
second sample of 50 unrelated individuals (median age 64 years) was unselected
and HPST scores were representative of the TwinsUK cohort HPST distribution
(Supplementary Fig. S1). Whole blood was collected after QST and DNA was
extracted using standard protocols. WBC subtype counts were obtained in 48
individuals from discovery sample using FACS of peripheral blood50. WBC subtype
cell counts were calculated for four cell types: neutrophils, eosinophils, monocytes
and lymphocytes.
MeDIP sequencing. MeDIP-seq was performed and analysed separately in the MZ
twin and unrelated samples. In the discovery MZ twin sample, 5 mg genomic DNA
from each sample was sonicated on a Diagenode Bioruptor to produce a median
fragment length of 180–230, and veriﬁed using a 2100 Bioanalyzer with DNA1000
chips (Agilent, Santa Clara, USA). Samples were prepared for next-generation
sequencing by blunt ending, dA-tailing and then ligating paired-end adapters
according to manufacturer’s reagents and protocols (Illumina) with puriﬁcation
(QIAGEN) between steps. Samples were quantiﬁed and size checked using a 2100
Bioanalyzer and DNA1000 chips (Agilent). One microgram of each adapter-ligated
sample was spiked with B5 10 7 pmoles methylated/unmethylated control
DNA (see ref. 51 for details) and subjected to MeDIP (ref. 52) with 150 ng anti-5-
methylcytidine using automation according to manufacturer’s reagents and
protocols (Diagenode); 100 ng was reserved as input for MeDIP quality control
(QC), which was conducted using quantitative PCR (qPCR) with primers designed
to amplify methylated/unmethylated control DNA. MeDIP DNA was then
puriﬁed (Zymo Research) and ampliﬁed by 18 cycles adapter-mediated PCR. PCR
products were puriﬁed (QIAGEN) and run out on separate 2% low-melting point
agarose gels. PCR fragments were excised and puriﬁed (QIAGEN). The resulting
libraries (300–350 bp) were QC using an Agilent 2100 Bioanalyzer and DNA1000
chips and qPCR (see ref. 53). The samples were sequenced on Illumina GA2,
using two lanes per sample, to produce on average 50 million paired-end reads
of length 50 bp.
In the unrelated samples, 1.5 mg of original genomic DNA was fragmented to
DNA smear between 200 and 500 bp using a Bioruptor NGS (Diagenode)
sonication system. End repair,oA4 base addition and adaptor ligation steps were
performed using Illumina’s Paired-End DNA Sample Prep kit following the
manufacturer’s instructions. Next, the methylated DNA fractions were immuno-
precipitated using the Magnetic Methylated DNA Immunoprecipitation Kit
(Diagenode, catalogue number: mc-magme-048) with small adjustments. Brieﬂy,
1.5 ml of each two control templates (methylated and unmethylated DNA controls)
with different sequences were mixed with adapter-ligated DNA and heat denatured
(95 C, 3min) in a ﬁnal reaction volume of 90 ml within the provided reagents of
24ml MagBuffer A and 6 ml MagBuffer B. Aliquot (7.5 ml) of the denatured genomic
DNA was saved as input and another 75 ml was immunoprecipitated with 5 ml of
prepared anti-5mC antibody and 20 ml of prepared Magbeads. The DNA–antibody
magbeads mixture was incubated overnight at 4 C on a rotating wheel. The DNA–
antibody magbeads mixture was then washed twice using each of 150ml ice-cold
MagWash Buffer-1 and washed once with 150ml of ice-cold MagWash Buffer-2.
For each buffer, the washing reaction was incubated for 4min at 4 C on a rotating
wheel. The input DNA and immunoprecipitated products were then in parallel
treated with protease K and puriﬁed with ZYMO DNA Clean & Concentrator-5
(ZYMO). The efﬁciency and sensitivity of immunoprecipitation reaction were
detected by qPCR using the enriched DNA and the unbound input DNA. MeDIP-
seq library was constructed by PCR ampliﬁcation with the enriched DNA as
template. PCR reaction was performed in 50 ml of reaction volume consisting of
20ml MeDIP-enriched DNA, 5ml of 2.5mM dNTP, 2 ml primers, 5 ml of 10 pfx
ampliﬁcation buffer, 2 ml of 50mM MgSO4, 15.2 ml sterilized water and 0.8 ml of
Platinum pfx DNA polymerase (Invitrogen). The programme of ampliﬁcation
was 94 C 2min, 10 cycles of 94 C 15 s, 62 C 30 s and 72 C 30 s, then prolong
with 10min at 72 C. The products could be kept at 12 C. The PCR products
were puriﬁed using Agencourt Ampure Beads (Beckman Coulter). After analysing
by the Bioanalyzer analysis system (Agilent) and quantiﬁed by the real time PCR,
the prepared library was sequenced using Illumina HiSeq2000 with SE50 read
length.
MeDIP-seq DNA methylation quantiﬁcation. In the discovery MZ twin sample,
we obtained on average 50 million paired-end reads of length 50 bp per individual.
Alignment to the human genome (hg18) was performed using Maq54 (v0.7.1). QC
of the aligned data took into account base quality scores (no exclusions), read
mapping scores (threshold maq q410), removal of duplicate paired-end (PE)
reads, proper PE pairing criteria and insert-size distribution checks (see
Supplementary Fig. S2 and Supplementary Methods). On average, 60% of reads
passed alignment QC per individual. We used the post-QC PE reads to reconstruct
MeDIP fragments per individual. We quantiﬁed coverage of MeDIP fragments per
base pair across the genome and binned coverage into overlapping 1-kb bins
(overlap of 500 bp). For each bin, we calculated a normalized methylation score, the
relative methylation quantiﬁcation (RMQ) score, which was the sum of the
MeDIP-fragment coverage of each base pair in that bin, divided by the overall
number of autosomal post-QC reads per individual. For pain-DMR analysis, we
only considered bins with RMQ variance40, where at least 10% of the sample had
RMQ scores 40. There were 5,260,672 autosomal 1-kb bins used in the discovery
pain-DMR analyses.
In the discovery sample, we also performed additional quantiﬁcations of
MeDIP-seq data, taking into account variation in the size distribution of MeDIP
fragments across individuals and variation in CpG density across genomic regions
(Supplementary Methods and Supplementary Figs S6 and S7). For fragment
analyses, we matched the distribution of MeDIP fragments across the 50
individuals to match a standardized distribution (Supplementary Methods), and in
the analyses controlling for CpG density, we used MEDIPS29 to calculate absolute
methylation scores (AMS). We used AMS to examine DNA methylation patterns
across the genome (Fig. 1), and we used AMS and fragment-corrected scores to
assess the reproducibility of pain DMRs to different MeDIP-seq quantiﬁcations
(Supplementary Figs S7 and S8).
In the unrelated samples, we obtained on average 25 million single-end reads of
length 50 bp per individual. Sequence alignment to the human genome (hg18) was
performed in Bwa55 (v0.5.9; Supplementary Fig. S3). Data were subject to QC
checks for base composition (no exclusions), read mapping quality (threshold bwa
q410) and removal of duplicate reads. On average, 53% of reads passed alignment
QC per individual. Post-QC single-end reads were then extended by 175 bp
equilaterally to produce MeDIP fragments of size 225 bp. We quantiﬁed coverage
of MeDIP fragments per base pair across the genome, and binned coverage per
base pair into overlapping 1-kb bins (overlap of 500 bp). For each bin, we
calculated the normalized methylation score (RMQ), and in the pain-DMR
analyses we only considered bins with RMQ variance40, where at least 10% of the
sample had RMQ scores 40. There were 5,312,714 autosomal 1-kb bins used in
the follow-up pain-DMR analyses.
DMR analyses. Pain-DMR analyses in the discovery MZ twin set were performed
using linear mixed-effects models in R (lme4 package). We regressed the RMQ
scores in each 1-kb bin on HPST as a ﬁxed effect, family as a random effect, and
with and without age as ﬁxed-effect covariate. Before performing the pain-DMR
regression, we normalized the RMQ scores to N(0,1), but results were also calcu-
lated using the raw RMQ scores (Supplementary Methods). In the discovery set,
additional genome-wide pain-DMR analyses also took into account MeDIP-seq
fragment variability and CpG density, and only considered speciﬁc genomic
categories such as CpG-islands, CpG-island shores and promoters (Supplementary
Methods). In the second sample of 50 unrelated individuals, we ﬁt linear models
regressing RMQ on HPST across the genome, with or without covariates such as
age and the ﬁrst three autosomal methylation principal components, as well as
including RMQ normalization (to N(0,1)). The ﬁnal pain-DMR results (Table 1)
include normalized (to N(0,1)) RMQ scores regressed on HPST.
MA of the MZ twin and unrelated samples was performed in GWAMA56, using
a ﬁxed-effect MA on the HPST pain-DMR regression betas. We report MAP-
DMRs at permutation-based MA signiﬁcance threshold of FDR¼ 5%. We
investigated evidence for heterogeneity in the MA using Cochran’s Q-statistic and
the I2-statistic57, and only considered results with no strong evidence for
heterogeneity (Cochran’s Q, P40.01 and I2o0.8) in the observed data and in the
permutations. For completeness and to account for heterogeneity, we also
performed a random-effects MA and found that the nine FDR 10% MAP-DMRs
were within the top-ranked 0.002% of results (Supplementary Table S7). We also
checked DMRs for potential mappability problems, but the MAP-DMRs did not
overlap previously reported unannotated high-copy-number regions, which may
result in alignment problems58.
To determine EWAS genome-wide signiﬁcance thresholds in the discovery and
replication samples, we performed 20 replicates of genome-wide permutations. In
each replicate, we permuted the HPST scores (preserving family structure in the
MZ twin sample) and performed the genome-wide EWAS analyses under the null,
and used these to calculate FDR 5% thresholds in the MZ twin and unrelated
EWAS. We then combined each pair of MZ twin and unrelated replicates by MA,
to determine the MA permutation-based FDR 5% threshold. Genome-wide
permutation-based FDR 5% thresholds were estimated for the MZ twin, unrelated
and MA results. In each case, FDR was determined as the fraction of signiﬁcant hits
in the permuted data compared with the observed data at each P-value threshold.
At each nominal P-value level, we pooled signiﬁcant hits across the 20 replicates,
divided by the number of replicates (20) and then divided by the number of
observed hits in the real data at this nominal P-value. There was some variability in
FDR estimates at the level of individual replicates, for example, random samples of
10 replicates resulted in MA FDR 5% thresholds ranging from P¼ 2.5 10 9 to
P¼ 1.0 10 12, whereas the FDR 5% threshold based on 20 replicates was
estimated at P¼ 2.0 10 11.
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For within-pair DNA methylation and HPST analyses in the discovery MZ twin
set, we calculated the difference in RMQ scores at each 1-kb bin between co-twins
in the 25 MZ twin pairs. We calculated Pearson’s and Spearman’s correlations of
the RMQ and HPST differences within the MZ twin pair. We also ﬁt a linear
model, regressing the normalized RMQ difference on the HPST difference with age
as covariate, and the results were similar.
To assess whether the MAP-DMRs identiﬁed in our study capture differential
proportion of whole-blood cell (WBC) subtypes, we compared DNA methylation
with WBC subtype proportions for neutrophils, eosinophils, monocytes and
lymphocytes. Blood-count DMR analyses were performed at the nine FDR 5%
MAP-DMRs in 48 individuals from the discovery set. We ﬁt a linear mixed-effect
model, regressing the normalized RMQ scores on WBC subtype proportion as a
ﬁxed effect and family as a random effect. Results are presented at a DMR
Bonferroni-corrected P-value¼ 0.05 (nominal P¼ 0.0056).
Illumina 450k DNA methylation. Illumina 450k data were obtained for 46
discovery sample individuals. We removed two outliers and performed principal-
component analysis, comparing the ﬁrst two principal components with potential
confounders, which identiﬁed methylation chip, position of the sample on the chip
and post-bisulphite conversion DNA concentration as potential confounders.
Therefore, in the pain DMR 450k EWAS analyses, we regressed DNA methylation
on HPST levels and included chip, order of sample on the chip, bisulphate-con-
verted DNA concentration and age as ﬁxed effect covariates, and family as random
effect. We excluded all probes that mapped to multiple locations within 2 bp
mismatches, resulting in 468,113 probes, and in the 450k EWAS analyses we also
excluded probes with missing data, which resulted in a 440,307 autosomal probes.
We permuted the data ten times to assess signiﬁcance of the genome-wide 450k
EWAS results.
We used two approaches to compare MeDIP-seq and Illumina 450k DNA
methylation levels. First, we considered CpG sites that overlapped the 1-kb MeDIP-
seq bins (457,045 probes). Second, to validate MeDIP-seq FDR 5% DMR effects in
the Illumina 450K results, we considered MeDIP-seq DMRs that were within
100 kb of a gene TSS. We compared the direction of methylation pain association
of the MeDIP-seq pain DMR and the direction of methylation pain association of
all the 450k CpG sites that were assigned to the same gene. For validation, both
MeDIP-seq and 450k DMRs had to be in the same direction and the 450k nominal
P surpass weak evidence for association. The DNA methylation data are available at
http://www.twinsuk.ac.uk/data-access/medipseq-data/ and under GEO accession
number GSE53130.
Bisulphite pyrosequencing. Bisulphite pyrosequencing DNA methylation in the
TRPA1 DMR genomic region was performed by a commercial laboratory service
(EpigenDx). Brieﬂy, 200–500 ng of genomic DNA was used for bisulphite
modiﬁcation using the Zymo Research EZ DNA Methylation Kit (Zymo Research),
according to manufacturer’s instructions. Converted genomic DNA was PCR
ampliﬁed using two sets of TRPA1 DMR unbiased primers, followed by pyr-
osequencing using PSQ HS96 (Biotage). Bisulphite pyrosequencing was performed
as previously described59. The Pyro Q-CpG methylation software (Qiagen) was
used to determine the percentage of DNA methylation at each CpG site.
Supplementary Table S8 provides the genomic location of the CpG sites
measured in the TRPA1 CpG-island shore DMR. PCR reaction details and
annealing temperatures for all bisulﬁte pyrosequencing reactions are also provided
in Supplementary Table S8.
Genotypes. Genotypes were available for 48 individuals in the discovery sample
and for 47 individuals in the follow-up sample. Genotypes were obtained on a
combination of Illumina platforms (HumanHap300, HumanHap610Q, 1M-Duo
and 1.2MDuo 1M custom arrays) and stringent QC checks were applied to these
data as previously described35. HapMap genotypes were imputed using Impute (v2
(ref. 60)) with two reference panels, P0 (HapMap2, rel 22, combined CEU, YRI and
ASN panels) and P1 (610Kþ , including the combined HumanHap610K and 1M
array). Altogether, there were 2,028,354 (discovery) and 2,054,344 (follow-up)
directly genotyped and imputed autosomal single-nucleotide polymorphisms
(SNPs), which were further ﬁltered for subsequent analyses.
Methylation QTLs. DNA meQTL analyses were performed in 47 individuals from
the follow-up set. We selected 1,889,799 common HapMap SNPs, either directly
genotyped or imputed (Impute info Z0.8), with minor allele frequency Z0.05. At
each MAP-DMR, we tested for association between DNA methylation levels using
RMQ scores in 1-kb bins, and genotypes at all SNPs within 100 kb of the bin (50 kb
on either side). We normalized DNA methylation levels (to (N(0,1)) and regressed
DNA methylation on genotype using an additive model. Potential MAP-DMRs
with meQTLs in cis were considered if there was at least one SNP associated with
DNA methylation levels at nominal signiﬁcance, and we report nominal P-values
of association.
Allele-speciﬁc methylation. ASM was estimated in 48 MZ discovery twins. We
obtained heterozygous genetic variants using all available data from directly
genotyped and imputed common variants, and exome-sequencing data available
for 22 unrelated individuals (44 MZ twins)61. In the HapMap-imputed genotypes,
we considered SNPs for ASM analysis if Impute infoZ0.8 and if the probability of
a heterozygous genotype Z0.5 in at least 50% of the sample. In the exome-
sequencing data, we used direct genotype calls61 using a depth threshold of eight
and selected variants that were heterozygous in at least 50% of the sample. There
were 3,099 heterozygous genetic variants in the exome-sequencing data and
278,304 heterozygous SNPs in the HapMap data, giving an overall ﬁnal set of
279,885 unique candidate heterozygous genetic variants. For each individual at
each of the 279,885 genetic variants, we scored the number of MeDIP-seq reads
spanning the reference and non-reference alleles using maq pileup with depth
coverageZ8 reads per variant. We used the frequency of the reference allele in the
MeDIP-seq data as a measure of ASM, and scored a site within an individual as
ASM only if the reference allele frequency was o0.25 or 40.75. Altogether,
potential ASM calls were obtained at 17,261 variants. We excluded all ASM
variants that fell in genomic regions reported to be problematic in alignment
(Supplementary Methods).
Blood–brain DNA methylation comparison. MeDIP-seq patterns from blood and
multiple brain tissues were obtained from two female donors37. The brain regions
included the inferior frontal gyrus, middle frontal gyrus, left frontal gyrus,
entorhinal cortex, superior temporal gyrus of the temporal cortex, visual cortex and
the cerebellum. To assess tissue speciﬁcity of methylation effects at the 100
top-ranked MAP-DMRs, we ﬁrst estimated the correlation between brain and
blood methylation levels, by using the mean methylation levels across both
individuals in all brain regions and in blood. We then considered regions to have
tissue-shared methylation if the methylation difference between blood and one
brain region was o10% of the overall blood methylation level, and under more
stringent criteria, if the mean difference between blood and all brain region was
o10% of the overall blood methylation level (see Supplementary Methods).
Gene expression. Gene expression data were obtained from skin samples in 341
twins from the MuTHER study35, which included MZ and dizygotic twin pairs and
unrelated individuals. Gene expression levels were measured using the Illumina
expression array HumanHT-12 version 3 as previously described35. Each sample
had three technical replicates and log2-transformed expression signals were
quantile normalized ﬁrst across three replicates of each individual, and second
by quantile normalization across all individuals. We used the transformed
normalized residuals of the log-transformed gene expression array signal in
downstream analysis.
References
1. Breivik, H., Collett, B., Ventafridda, V., Cohen, R. & Gallacher, D. Survey of
chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J.
Pain 10, 287–333 (2006).
2. Tripp, D. A., VanDenKerkhof, E. G. & McAlister, M. Prevalence and
determinants of pain and pain-related disability in urban and rural settings in
southeastern Ontario. Pain Res. Manag. 11, 225–233 (2006).
3. Nielsen, C. S., Price, D. D., Vassend, O., Stubhaug, A. & Harris, J. R.
Characterizing individual differences in heat-pain sensitivity. Pain 119, 65–74
(2005).
4. Nassar, M. A. et al. Nociceptor-speciﬁc gene deletion reveals a major role for
Nav1.7 (PN1) in acute and inﬂammatory pain. Proc. Natl Acad. Sci. USA 101,
12706–12711 (2004).
5. Priest, B. T. et al. Contribution of the tetrodotoxin-resistant voltage-gated
sodium channel NaV1.9 to sensory transmission and nociceptive behavior.
Proc. Natl Acad. Sci. USA 102, 9382–9387 (2005).
6. Nielsen, C. S. et al. Individual differences in pain sensitivity: genetic and
environmental contributions. Pain 136, 21–29 (2008).
7. Norbury, T. A., MacGregor, A. J., Urwin, J., Spector, T. D. & McMahon, S. B.
Heritability of responses to painful stimuli in women: a classical twin study.
Brain 130, 3041–3049 (2007).
8. Zubieta, J. K. et al. COMT val158met genotype affects mu-opioid
neurotransmitter responses to a pain stressor. Science 299, 1240–1243 (2003).
9. Foulkes, T. & Wood, J. N. Pain genes. PLoS Genet. 4, e1000086 (2008).
10. Young, E. E., Lariviere, W. R. & Belfer, I. Genetic basis of pain variability: recent
advances. J. Med. Genet. 49, 1–9 (2012).
11. Crow, M., Denk, F. & McMahon, S. B. Genes and epigenetic processes as
prospective pain targets. Genome Med. 5, 12 (2013).
12. Denk, F. & McMahon, S. B. Chronic pain: emerging evidence for the
involvement of epigenetics. Neuron 73, 435–444 (2012).
13. Rakyan, V. K., Down, T. A., Balding, D. J. & Beck, S. Epigenome-wide
association studies for common human diseases. Nat. Rev. Genet. 12, 529–541
(2011).
14. Dempster, E. L. et al. Disease-associated epigenetic changes in monozygotic
twins discordant for schizophrenia and bipolar disorder. Hum. Mol. Genet. 20,
4786–4796 (2011).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3978 ARTICLE
NATURE COMMUNICATIONS | 5:2978 | DOI: 10.1038/ncomms3978 |www.nature.com/naturecommunications 9
& 2014 Macmillan Publishers Limited. All rights reserved.
15. Gervin, K. et al. DNA methylation and gene expression changes in
monozygotic twins discordant for psoriasis: identiﬁcation of epigenetically
dysregulated genes. PLoS Genet. 8, e1002454 (2012).
16. Rakyan, V. K. et al. Identiﬁcation of type 1 diabetes-associated DNA
methylation variable positions that precede disease diagnosis. PLoS Genet. 7,
e1002300 (2011).
17. Valencia, C., Fillingim, R. B. & George, S. Z. Suprathreshold heat pain response
is associated with clinical pain intensity for patients with shoulder pain. J. Pain
12, 133–140 (2011).
18. Cochran, W. G. The combination of estimates from different experiments.
Biometrics 10, 101–129 (1954).
19. Han, B. & Eskin, E. Interpreting meta-analyses of genome-wide association
studies. PLoS Genet. 8, e1002555 (2012).
20. Barrett, J. C. et al. Genome-wide association study and meta-analysis ﬁnd that
over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41, 703–707 (2009).
21. Zeggini, E. et al. Meta-analysis of genome-wide association data and large-scale
replication identiﬁes additional susceptibility loci for type 2 diabetes. Nat.
Genet. 40, 638–645 (2008).
22. Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of
conﬁrmed Crohn’s disease susceptibility loci. Nat. Genet. 42, 1118–1125 (2010).
23. Kaminsky, Z. A. et al. DNA methylation proﬁles in monozygotic and dizygotic
twins. Nat. Genet. 41, 240–245 (2009).
24. Steiner, E. et al. The major vault protein is responsive to and interferes with
interferon-gamma-mediated STAT1 signals. J. Cell Sci. 119, 459–469 (2006).
25. Tsuda, M. et al. IFN-gamma receptor signaling mediates spinal microglia
activation driving neuropathic pain. Proc. Natl Acad. Sci. USA 106, 8032–8037
(2009).
26. Zhou, D. et al. AnkyrinG is required for clustering of voltage-gated Na channels
at axon initial segments and for normal action potential ﬁring. J. Cell Biol. 143,
1295–1304 (1998).
27. Ferreira, M. A. et al. Collaborative genome-wide association analysis supports a
role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40, 1056–1058
(2008).
28. Nair, H. K. et al. Genomic loci and candidate genes underlying inﬂammatory
nociception. Pain 152, 599–606 (2011).
29. Chavez, L. et al. Computational analysis of genome-wide DNA methylation
during the differentiation of human embryonic stem cells along the endodermal
lineage. Genome Res. 20, 1441–1450 (2010).
30. Sandoval, J. et al. Validation of a DNA methylation microarray for 450,000
CpG sites in the human genome. Epigenetics 6, 692–702 (2011).
31. Fajardo, O., Meseguer, V., Belmonte, C. & Viana, F. TRPA1 channels mediate
cold temperature sensing in mammalian vagal sensory neurons:
pharmacological and genetic evidence. J. Neurosci. 28, 7863–7875 (2008).
32. Kwan, K. Y. et al. TRPA1 contributes to cold, mechanical, and chemical
nociception but is not essential for hair-cell transduction. Neuron 50, 277–289
(2006).
33. Fernandes, E. S., Fernandes, M. A. & Keeble, J. E. The functions of TRPA1 and
TRPV1: moving away from sensory nerves. Br. J. Pharmacol. 166, 510–521
(2012).
34. Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and
beyond. Nat. Rev. Genet. 13, 484–492 (2012).
35. Grundberg, E. et al. Mapping cis and trans regulatory effects across multiple
tissues in twins:. Nat. Genet. 10, 1084–1089 (2012).
36. Patil, M. J., Jeske, N. A. & Akopian, A. N. Transient receptor potential V1
regulates activation and modulation of transient receptor potential A1 by
Ca2þ . Neuroscience 171, 1109–1119 (2010).
37. Davies, M. N. et al. Functional annotation of the human brain methylome
identiﬁes tissue-speciﬁc epigenetic variation across brain and blood. Genome
Biol. 13, R43 (2012).
38. Kang, K. et al. Modulation of TRPA1 thermal sensitivity enables sensory
discrimination in Drosophila. Nature 481, 76–80 (2012).
39. Zhong, L. et al. Thermosensory and non-thermosensory isoforms of Drosophila
melanogaster TRPA1 reveal heat sensor domains of a thermoTRP channel. Cell
Rep. 1, 43–55 (2012).
40. Neely, G. G. et al. TrpA1 regulates thermal nociception in Drosophila. PLoS
One 6, e24343 (2011).
41. Lee, Y. C. et al.Molecular cloning and functional expression of two members of
mouse NeuAcalpha2,3Galbeta1,3GalNAc GalNAcalpha2,6-sialyltransferase
family, ST6GalNAc III and IV. J. Biol. Chem. 274, 11958–11967 (1999).
42. Lee, K. T. et al. Neuronal genes for subcutaneous fat thickness in human and
pig are identiﬁed by local genomic sequencing and combined SNP association
study. PLoS One 6, e16356 (2011).
43. Zhou, Y., Gunput, R. A., Adolfs, Y. & Pasterkamp, R. J. MICALs in control of
the cytoskeleton, exocytosis, and cell death. Cell. Mol. Life Sci. 68, 4033–4044
(2011).
44. Beuchle, D., Schwarz, H., Langegger, M., Koch, I. & Aberle, H. Drosophila
MICAL regulates myoﬁlament organization and synaptic structure. Mech. Dev.
124, 390–406 (2007).
45. Kirilly, D. et al. A genetic pathway composed of Sox14 and Mical governs
severing of dendrites during pruning. Nat. Neurosci. 12, 1497–1505 (2009).
46. Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: a tool for
discovery and visualization of enriched GO terms in ranked gene lists. BMC
Bioinformatics 10, 48 (2009).
47. Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell
mixture distribution. BMC Bioinformatics 13, 86 (2012).
48. Lowe, R. et al. Buccals are likely to be a more informative surrogate tissue than
blood for epigenome-wide association studies. Epigenetics 8, 445 (2013).
49. Moayyeri, A., Hammond, C. J., Valdes, A. M. & Spector, T. D. Cohort
proﬁle: TwinsUK and Healthy Ageing Twin Study. Int. J. Epidemiol. 42, 76–85
(2012).
50. Nalls, M. A. et al. Multiple loci are associated with white blood cell phenotypes.
PLoS Genet. 7, e1002113 (2011).
51. Butcher, L. M. & Beck, S. AutoMeDIP-seq: a high-throughput, whole genome,
DNA methylation assay. Methods 52, 223–231 (2010).
52. Weber, M. et al. Chromosome-wide and promoter-speciﬁc analyses identify
sites of differential DNA methylation in normal and transformed human cells.
Nat. Genet. 37, 853–862 (2005).
53. Quail, M. A. et al. A large genome center’s improvements to the Illumina
sequencing system. Nat. Methods 5, 1005–1010 (2008).
54. Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and
calling variants using mapping quality scores. Genome Res. 18, 1851–1858
(2008).
55. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
56. Magi, R. & Morris, A. P. GWAMA: software for genome-wide association
meta-analysis. BMC Bioinformatics 11, 288 (2010).
57. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis.
Stat. Med. 21, 1539–1558 (2002).
58. Pickrell, J. K., Gaffney, D. J., Gilad, Y. & Pritchard, J. K. False positive peaks in
ChIP-seq and other sequencing-based functional assays caused by unannotated
high copy number regions. Bioinformatics 27, 2144–2146 (2011).
59. Tost, J. & Gut, I. G. DNA methylation analysis by pyrosequencing. Nat. Protoc.
2, 2265–2275 (2007).
60. Howie, B. N., Donnelly, P. & Marchini, J. A ﬂexible and accurate genotype
imputation method for the next generation of genome-wide association studies.
PLoS Genet. 5, e1000529 (2009).
61. Williams, F. M. K. et al. Genes contributing to pain sensitivity in the
normal population: an exome sequencing study. PLoS Genet. 8, e1003095
(2012).
Acknowledgements
We thank the twins for their voluntary contribution to this project. We acknowledge staff
of the Department of Twin Research (DTR) and funding agencies that provided DTR
support for this project, including The Wellcome Trust and the National Institute for
Health Research (NIHR) Biomedical Research Centre (BRC) award to Guy’s & St
Thomas’ NHS Foundation Trust in partnership with King’s College London. We thank
M. Poulin and L. Yan (EpigenDx) for performing bisulphite pyrosequencing. Research in
the Beck laboratory was supported by the following: Wellcome Trust (084071), Royal
Society Wolfson Research Merit Award (WM100023) and EU-FP7 projects EPI-
GENESYS (257082), EpitTrain (316758), and BLUEPRINT (282510). J.T.B. was funded
by a Sir Henry Wellcome postdoctoral fellowship. T.D.S. is an NIHR Senior Investigator
and a European Research Council Senior Research Investigator (ERC 250157).
Author contributions
T.D.S., S.J., J.T.B. and W.J. designed the study. L.M.B., G.F., J.S., H.W. and N.L.
performed the experiments. K.W., J.H., S.S., M.D., L.C.S., J.M., F.M.K.W., P.D., S.B. and
S.M. contributed reagents, materials and analysis tools. J.T.B. analysed the data with
contributions from B.Z., A.K.L. and C.L.H. J.T.B. and T.D.S. wrote the paper. All authors
read and approved the manuscript before submission. T.D.S., S.J. and W.J. contributed
equally to the study.
Additional information
Accession codes: The sequence and microarray data have been deposited in the NCBI
Gene Expression Omnibus under GEO accession number GSE53130. All data sets are
also available at http://www.twinsuk.ac.uk/data-access/medipseq-data/.
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: Authors A.K.L., B.Z., C.L.H., S.S. and S.L.J. are employees
of Pﬁzer Inc. All other authors declare no competing ﬁnancial interest.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3978
10 NATURE COMMUNICATIONS | 5:2978 |DOI: 10.1038/ncomms3978 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
How to cite this article: Bell, J. T. et al. Differential methylation of the TRPA1
promoter in pain sensitivity. Nat. Commun. 5:2978 doi: 10.1038/ncomms3978
(2014).
This article is licensed under a Creative Commons Attribution 3.0
Unported Licence. To view a copy of this licence visit http://
creativecommons.org/licenses/by/3.0/.
Kourosh R. Ahmadi1, Chrysanthi Ainali15, Amy Barrett16, Veronique Bataille1, Jordana T. Bell1, Alfonso Buil17,
Panos Deloukas10, Emmanoil T. Dermitzakis17, Antigone S. Dimas2,17,18,19, Richard Durbin10, Daniel Glass1,
Elin Grundberg1,10, Neelam Hassanali16, Asa K. Hedman2, Catherine Ingle10, David Knowles20, Maria
Krestyaninova21, Cecilia M. Lindgren2, Christopher E. Lowe22,23, Mark I. McCarthy16,2,24, Eshwar Meduri1,10,
Paola di Meglio19, Josine L. Min2, Stephen B. Montgomery17, Frank O. Nestle19, Alexandra C. Nica17, James
Nisbet10, Stephen O’Rahilly22,23, Leopold Parts10, Simon Potter10, Magdalena Sekowska10, So-Youn Shin10, Kerrin
S. Small1,10, Nicole Soranzo10, Tim D. Spector1, Gabriela Surdulescu1, Mary E. Travers16, Loukia Tsaprouni10,
Sophia Tsoka15, Alicja Wilk6, Tsun-Po Yang10, Krina T. Zondervan2
15Department of Informatics, School of Natural and Mathematical Sciences, King’s College London, London, WC2R 2LS, UK. 16Oxford Centre for Diabetes,
Endocrinology & Metabolism, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK. 17Department of Genetic Medicine and Development, University
of Geneva Medical School, Geneva, 1211, Switzerland. 18Biomedical Sciences Research Center Al. Fleming 16672 Vari, Greece. 19St. John’s Institute of
Dermatology, King’s College London, London, SE1 9RT, UK. 20University of Cambridge, Cambridge, CB3 0WA, UK. 21European Bioinformatics Institute,
Hinxton, CB10 1SD, UK. 22University of Cambridge Metabolic Research Labs, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, CB2 0QQ,
UK. 23Cambridge NIHR Biomedical Research Centre, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK. 24Oxford NIHR Biomedical Research Centre,
Churchill Hospital, Oxford, OX3 7LE, UK
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3978 ARTICLE
NATURE COMMUNICATIONS | 5:2978 | DOI: 10.1038/ncomms3978 |www.nature.com/naturecommunications 11
& 2014 Macmillan Publishers Limited. All rights reserved.
